Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc demonstrated positive financial momentum, recording a 21% increase in top-line growth in Q3, driven by a 13% rise in volume and a 5% increase in average selling prices (ASPs). The company achieved its highest quarterly cash collections in history during October and has expanded its sales force by approximately 50%, positioning itself for further growth in volumes. With consistent year-over-year growth in kidney surveillance volumes and the recent achievement of GAAP net income positivity, CareDx has raised its financial guidance, reflecting a strong outlook for continued performance.

Bears say

CareDx Inc. has reported a year-over-year volume increase of 13% for Q3'25, but the volumes fell short of expectations, indicating potential market challenges and seasonal slowdowns. The stock is currently trading at a significant discount to historical averages, raising concerns about the company's ability to capitalize on growth opportunities amidst ongoing risks associated with management turnover and the commercialization of new diagnostic solutions. Additionally, uncertainties regarding potential changes in Medicare coverage for kidney testing could further complicate CareDx's revenue trajectory and strategic growth initiatives.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.